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eripherin, a neuronal intermediate ﬁlament (nIF) protein
found associated with pathological aggregates in
motor neurons of patients with amyotrophic lateral
sclerosis (ALS) and of transgenic mice overexpressing
mutant superoxide dismutase-1 (SOD1
 
G37R
 
), induces the
selective degeneration of motor neurons when overexpressed
in transgenic mice. Mouse peripherin is unique compared
with other nIF proteins in that three peripherin isoforms are
generated by alternative splicing. Here, the properties of
the peripherin splice variants Per 58, Per 56, and Per 61
have been investigated in transfected cell lines, in primary
motor neurons, and in transgenic mice overexpressing
P
 
peripherin or overexpressing SOD1
 
G37R
 
. Of the three isoforms,
Per 61 proved to be distinctly neurotoxic, being assembly
incompetent and inducing degeneration of motor neurons
in culture. Using isoform-speciﬁc antibodies, Per 61 expres-
sion was detected in motor neurons of SOD1
 
G37R
 
 transgenic
mice but not of control or peripherin transgenic mice. The
Per 61 antibody also selectively labeled motor neurons and
axonal spheroids in two cases of familial ALS and immuno-
precipitated a higher molecular mass peripherin species
from disease tissue. This evidence suggests that expression
of neurotoxic splice variants of peripherin may contribute
to the neurodegenerative mechanism in ALS.
 
Introduction
 
Amyotrophic lateral sclerosis (ALS)* is an adult onset neuro-
logical disorder that affects primarily motor neurons of the
brain stem and spinal cord, resulting in paralysis and death
within 2–5 yr. Although most cases of ALS are sporadic,
15–20% are familial and, of these, 1–2% are caused by
mutations within the gene encoding the metalloenzyme
Cu/Zn superoxide dismutase-1 (
 
SOD1
 
; Rosen et al., 1993).
The mechanism by which expression of mutant SOD1 induces
motor neuron degeneration remains elusive. 
An ultrastructural hallmark of diseased motor neurons in
ALS is the presence of perikaryal and axonal aggregates com-
posed of the neuronal intermediate filaments (nIFs), neuro-
filaments, and peripherin (Carpenter, 1968; Corbo and
Hays, 1992; Migheli et al., 1993). Neurofilaments are
formed by the coassembly of three type IV nIF proteins,
neurofilament light subunit (NF-L; 68–70 kD), neurofilament
medium subunit (NF-M; 150–155 kD); and neurofilament
heavy subunit (NF-H; 200–210 kD), and are widely expressed
throughout the central and peripheral nervous systems
(Julien and Mushynski, 1998). Peripherin is an 
 
 
 
58-kD
type III nIF protein that is capable of self-assembly and is
expressed mostly in the peripheral nervous system and only
at low levels in defined neuronal populations of the central
nervous system (Portier et al., 1983a, 1993; Parysek and
Goldman, 1988; Brody et al., 1989; Escurat et al., 1990).
However, after neuronal injury, peripherin expression is
increased; e.g., in large dorsal root ganglion neurons and spinal
motor neurons after sciatic nerve crush (Troy et al., 1990;
Wong and Oblinger, 1990), and also in neuronal populations
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of the brain after lesion injury or cerebral ischemia (Beaulieu
et al., 2002). This increase in peripherin expression has been
suggested to facilitate neuronal regeneration (Troy et al.,
1990; Wong and Oblinger, 1990).
To study the potential contribution of abnormalities in nIF
expression to motor neuron degeneration in ALS, numerous
transgenic mouse models have been developed in which the
different nIF genes have been overexpressed or knocked out
(for review see Cleveland and Rothstein, 2001; Julien, 2001).
Of all these models involving wild-type nIF proteins, only the
peripherin transgenic mouse develops a motor neuron degen-
eration mimicking several aspects of ALS, including the for-
mation of peripherin immunoreactive aggregates and the se-
lective loss of motor neurons (Beaulieu et al., 1999a). These
findings indicate that in addition to its possible involvement
in regeneration, peripherin also has toxic properties that can
lead to neuronal degeneration.
Peripherin is unique compared with other nIF proteins in
that three mRNA alternative splice variants and their corre-
sponding translation products have been identified in a
mouse neuroblastoma cell line (Landon et al., 1989, 2000).
Per 58, the naming reflective of its molecular mass in kilo-
Daltons on SDS–polyacrylamide gels, corresponds to the
peripherin species first identified in mouse neuroblastoma
and rat PC12 cells (Portier et al., 1983a), and is encoded by
all nine exons of the peripherin gene. Per 61 is identical to
Per 58 except for the insertion of a 32–amino acid sequence
in coil 2 of the 
 
 
 
-helical rod domain, signifying the inclu-
sion of 96 bp of intron 4. Per 56 is generated by the use of a
cryptic acceptor site at the beginning of exon 9, resulting in
a frameshift and replacement of the COOH-terminal 21
amino acids of Per 58 with a unique 8–amino acid sequence.
Why these different peripherin isoforms exist is unknown,
and the expression of Per 56 and Per 61 at the protein level
has not previously been demonstrated in vivo. However, it is
possible that they have different functional properties such
that their differential expression may induce distinct conse-
quences to the neuron in which they are expressed.
Here, we have investigated the properties of Per 58, Per
56, and Per 61 in cell lines and in primary motor neurons.
We show that each peripherin isoform has different assem-
bly characteristics and that, more importantly, Per 61 is neu-
rotoxic when expressed in motor neurons in primary cul-
ture. Using isoform-specific antibodies, we show that Per 61
is expressed in motor neurons of mutant SOD1
 
G37R
 
 trans-
genic mice but not of wild-type control or peripherin trans-
genic mice, demonstrating that the disease mechanism of
mutant SOD1
 
G37R
 
 includes expression of a neurotoxic splice
variant of peripherin. The Per 61 antibody also labeled
pathological lesions in the lumbar spinal cord of ALS cases
but not of control. Moreover, the Per 61 antibody immuno-
precipitated a higher molecular mass peripherin species, sug-
gesting that expression of alternatively spliced variants of
peripherin may contribute to the neurodegenerative mecha-
nism in ALS.
 
Results
 
Assembly properties of peripherin isoforms 
in transfected SW13 vim(
 
 
 
) cells
 
Alternative splicing of the mouse peripherin gene tran-
script generates at least three peripherin isoforms, Per 58,
Per 61, and Per 56 (Fig. 1; Landon et al., 1989, 2000).
The specific assembly characteristics of the peripherin iso-
forms have not been investigated previously. Here, the as-
sembly properties of the individual peripherin isoforms
were analyzed in SW13 vim(
 
 
 
) cells, an adrenal carcinoma
cell line that lacks an endogenous cytoplasmic intermediate
filament (IF) network (Sarria et al., 1994). Ectopic expres-
sion of cDNAs encoding the different peripherin isoforms
generated proteins of the expected molecular masses in cell
extracts analyzed by SDS-PAGE, i.e., 58 kD for Per 58; 56
kD for Per 56; and 61 kD for Per 61 (Fig. 2 A). Immuno-
cytochemical analysis of the cytoplasmic distribution of the
expressed peripherin isoforms revealed that both Per 56
and Per 58 were capable of self-assembly, forming IF net-
works, whereas Per 61 was assembly incompetent, forming
aggregates (Fig. 2 B). Furthermore, although Per 56 and
Per 58 were capable of coassembly into a filamentous net-
work, expression of Per 61 with either Per 56 or Per 58 in-
duced aggregation (unpublished data).
As peripherin and neurofilaments are coexpressed in sev-
eral neuronal cell types both normally and after injury, it is
important to investigate the potential interactions between
Figure 1. Alternative splicing of the 
mouse peripherin gene. The peripherin 
gene contains nine exons, with the 
intron-exon location categorizing it as 
a type III intermediate filament protein 
(IFP). As with other IFPs, peripherin has 
an  -helical rod domain flanked by 
non– -helical NH2-terminal head and 
COOH-terminal tail domains. The pre-
dominant isoform, Per 58, is encoded 
by all nine exons of the peripherin gene 
to generate a protein of 475 aa, using 
the nomenclature of Landon et al. (2000) 
in which the first of three potential ATG 
initiation codons is used as the start site. 
The retention of intron 4, which is 96 bp 
in length, generates Per 61, corresponding 
to a 32-aa insertion in coil 2 of the  -helical rod domain. Isoform Per 56 is generated by the use of a cryptic acceptor site at the beginning 
of exon 9, leading to a deletion of 62 bp, a change in reading frame, and a replacement of the COOH-terminal 21 aa with a unique 8-aa sequence.T
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these filament types especially in relation to aggregate forma-
tion, which is associated with numerous pathological condi-
tions including ALS. We have shown previously, in cotrans-
fection studies in SW13 vim(
 
 
 
) cells using the mouse
peripherin gene, that peripherin is not only assembly com-
petent but can also coassemble with NF-L (Beaulieu et al.,
1999b). However, coexpression of NF-H or NF-M with pe-
ripherin causes disruption of filament assembly (Beaulieu et
Figure 2. Expression of peripherin isoforms in 
transfected SW13 vim( ) cells. (A) Mammalian 
expression plasmids encoding the peripherin iso-
forms, Per 58, Per 56, or Per 61, and also the full-
length peripherin gene (Per gene) were transfected 
into SW13 vim( ) cells and harvested 48 h later. 
Equal protein loadings (10  g) of harvested cells were resolved on 7.5% (wt/vol) SDS–polyacrylamide gels, and then transferred to PVDF 
membrane and probed with a monoclonal antibody recognizing peripherin (MAB1527). For Per 61, immunoprecipitation using peripherin 
polyclonal antiserum (AB1530) was used to obtain sufficient quantities for detection on immunoblots. The immunoblot shows that expression 
of the plasmids encoding Per 58, Per 56, and Per 61, as indicated, generate proteins of the expected molecular masses with the position of the 
62-kD marker shown (arrow). The major peripherin species expressed from the full-length peripherin gene (Per gene) corresponds to the molecular 
mass of isoform Per 58. (B) SW13 vim( ) cells transfected with the individual peripherin isoform expression plasmids were labeled immuno-
cytochemically with monoclonal antibody to peripherin (MAB1527) to ascertain the cytoplasmic distribution of the expressed proteins. From 
the figure it can be seen that both Per 58 and Per 56 were capable of self-assembly to form an IF network that was distributed evenly throughout 
the cytoplasm. These results are similar to those obtained with the full-length mouse peripherin gene (Beaulieu et al., 1999b). In contrast, Per 
61 was assembly incompetent, forming aggregates of uneven size and distribution. Bar, 10  m.
Figure 3. Assembly characteristics of 
peripherin isoforms in transfected SW13 
vim( ) cells. SW13 vim( ) cells were 
transfected with expression plasmids 
encoding the different peripherin isoforms 
together with plasmids encoding NF-L, 
NF-M, or NF-H. Assembly properties of 
the coexpressed proteins were analyzed 
by double immunofluorescence labeling 
using monoclonal antibody to peripherin 
(MAB1527; red) and polyclonal antiserum 
(green) to NF-L (AB1983), NF-M (AB1981), 
and NF-H (AB 1982) in the respective 
cotransfected cells. Isoforms Per 58 and 
Per 56 were capable of coassembly with 
all three neurofilament subunits (A, A ; 
B, B ; D, D ; E, E ; I, I ; and J, J ), whereas 
isoform Per 61 was incapable of co-
assembly into an IF network with any 
of the neurofilament subunits (C, C ; H, 
H ; and O, O ). Additional phenotypes 
were observed in cells cotransfected 
with Per 58 or Per 56 and NF-M or NF-H. 
These were filamentous bundles of 
peripherin in the presence of nonassem-
bled NF-M (F, F  and G, G ) or NF-H 
(K, K  and L, L ; arrows in K indicate 
filaments) and nonassembled Per 58 or 
Per 56 in the presence of nonassembled 
NF-H (M, M  and N, N ). Bar, 14  m.T
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al., 1999b). We compared the coassembly properties of each
of the peripherin isoforms with the individual neurofilament
subunits, NF-L, NF-M, and NF-H. Per 56 and 58 were ca-
pable of coassembly with all three neurofilament subunits
(Fig. 3, A, A
 
 
 
; B, B
 
 
 
; D, D
 
 
 
; E, E
 
 
 
; I, I
 
 
 
; and J, J
 
 
 
). However,
there were additional phenotypes observed in which Per 56
or Per 58 formed filamentous bundles in the presence of
nonfilamentous NF-M (Fig. 3, F, F
 
 
 
; and G, G
 
 
 
). This was
also observed in cells cotransfected with Per 56 or Per 58
and NF-H (Fig. 3, K, K
 
 
 
; and L, L
 
 
 
). A further phenotype
observed in Per 56/NF-H– or Per 58/NF-H–cotransfected
cells was the presence of punctate peripherin together with
punctate NF-H (Fig. 3, M, M
 
 
 
; and N, N
 
 
 
). As the SW13
vim(
 
 
 
) cells used for this study were a clonal cell line used
within two to seven passages, we concluded that these differ-
ences were attributable to differences in the relative expres-
sion levels of peripherin and/or the neurofilament subunits.
Per 61 was incompetent for IF assembly with all three
neurofilament subunits (Fig. 3, C, C
 
 
 
; H, H
 
 
 
; and O, O
 
 
 
).
Of note was the difference in cytoplasmic distribution of Per
61 in SW13 vim(
 
 
 
) cells cotransfected with NF-L com-
pared with those transfected with Per 61 alone or together
with NF-M or NF-H (compare Fig. 2 and Fig. 3, H and O,
with Fig. 3 C). In Per 61/NF-L–cotransfected cells, the dis-
tribution of Per 61 was more granular and appeared more
evenly dispersed throughout the cytoplasm in contrast to a
more speckled phenotype in cells transfected with Per 61
alone. We also observed that coexpression with NF-L ap-
peared to “stabilize” Per 61, with a greater number of cells
appearing transfected after immunocytochemical labeling
and a higher yield of Per 61 apparent on immunoblots (un-
published data).
 
Expression of Per 61 is neurotoxic to motor neurons 
in culture
 
Overexpression of peripherin in transgenic mice leads to late
onset and selective degeneration of motor neurons (Beaulieu
et al., 1999a). Furthermore, we have recently shown, using
intranuclear microinjection studies, that overexpression of
peripherin induces death of motor neurons in culture (Rob-
ertson et al., 2001). To directly test the effect of individual
peripherin isoform expression on motor neuron viability, ex-
pression plasmids encoding each peripherin isoform were
microinjected into motor neuron nuclei in primary culture
(Durham et al., 1997). Motor neurons in dissociated spinal
cord cultures do not express peripherin (Robertson et al.,
2001); therefore, the expression of the peripherin isoforms
individually microinjected into motor neurons could be de-
tected with commercially available antibody to peripherin
(MAB1527). The viability curve in Fig. 4 A shows that Per
61 is extremely toxic to motor neurons. Almost all of the
motor neurons were dead after only 7-d expression of the
Per 61 plasmid. In contrast, the effect of Per 58 and Per 56
expression on viability of motor neurons was not signifi-
cantly different from control, in which the expression plas-
mid (pRcCMV) alone was microinjected. Immunocyto-
chemical analyses of microinjected motor neurons with
antibodies recognizing peripherin or NF-L revealed that
both Per 58 and Per 56 could integrate normally into the ex-
isting nIF network (Fig. 4, B and C), whereas Per 61 formed
aggregates similar to those observed in SW13 vim(
 
 
 
) cells
transfected with Per 61 expression plasmid (compare Fig. 4
C with Fig. 2 B). In addition, motor neurons expressing Per
61 appeared shrunken with few neuritic processes, changes
consistent with neurotoxicity and neuronal death (Fig. 4 B).
These findings show that expression of Per 61, and not Per
58 or Per 56, is neurotoxic when expressed in motor neu-
rons in culture.
 
Expression of Per 56 but not Per 61 in motor neurons 
of peripherin transgenic mice
 
Peripherin aggregates are a feature of transgenic mice overex-
pressing peripherin and of transgenic mice overexpressing
mutant SOD1
 
G37R
 
 (Tu et al., 1996; Julien and Beaulieu,
2000). To analyze the contribution of Per 56 and Per 61 to
the formation of these aggregates, synthetic peptides corre-
sponding to the unique sequences in Per 61 and Per 56 were
used to generate isoform-specific antibodies. As there is no
unique sequence in Per 58, it was not possible to generate an
antiserum specifically recognizing this isoform. Therefore,
we could not establish if there was a specific increase in Per
58 expression in motor neurons of peripherin or SOD1
 
G37R
 
transgenic mice using this approach. The Per 56 and Per 61
antibodies were purified by affinity chromatography and
their specificity was tested by immunocytochemistry (Fig. 5,
A–F) and immunoblotting (Fig. 5 G) using SW13 vim(
 
 
 
)
cells expressing either Per 56, Per 58, or Per 61. Immunocy-
tochemical labeling of the transfected SW13 vim(
 
 
 
) cells
with anti–Per 56 and anti–Per 61 revealed that both antisera
were specific for their respective immunogens (Fig. 5, D and
E). There was no cross-reactivity of anti–Per 61 with either
Per 58 or Per 56 (Fig. 5, A and C) and conversely anti–Per
56 did not detect Per 61 or Per 58 (Fig. 5, B and F). These
findings were also confirmed immunocytochemically in sim-
ilar experiments performed on microinjected motor neurons
(unpublished data). Immunoblotting with polyclonal pe-
ripherin antiserum (AB1530) established the expression of
the different peripherin isoforms in cell extracts of Per 58–
transfected (Fig. 5 G, lane 1), Per 56–transfected (Fig. 5 G,
lane 2), and Per 61–transfected (Fig. 5 G, lane 3) SW13 vim
(
 
 
 
) cells. Probing of the same samples with anti–Per 61 or
anti–Per 56 confirmed the specificity of the isoform-specific
antisera (Fig. 5 G).
Transgenic mice overexpressing the mouse peripherin
gene develop a motor neuropathy with features mimicking
some aspects of ALS, specifically the loss of motor neurons
in the spinal cord, precipitated by the formation of periph-
erin aggregates both in motor axons and perikarya (Beaulieu
et al., 1999a). Lumbar spinal cord sections from two differ-
ent lines of peripherin transgenic mice, Per and Per;LKO to-
gether with wild-type mice (C57Bl6), were labeled with
anti–Per 56 and anti–Per 61. Motor neuron death induced
by overexpression of peripherin is exacerbated by the loss of
NF-L in Per;LKO transgenic mice (Beaulieu et al., 1999a)
and lack of NF-L may affect peripherin isoform expression.
There was a small amount of labeling of motor neurons
with anti–Per 56 in wild-type tissue and more intense label-
ing in both lines of peripherin transgenic mice (Fig. 6). In
the Per;LKO transgenic mouse tissue, there was a greater
propensity for peripherin aggregation compared with theT
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corresponding peripherin labeling in Per transgenic mice
(Fig. 6, compare C with E), as had been observed previously
with peripherin polyclonal antiserum, AB1530 (Beaulieu et
al., 1999b). In contrast, there was no detectable labeling of
either wild-type or peripherin transgenic mouse motor neu-
rons (Per and Per;LKO) with antibody recognizing Per 61
(Fig. 6, D and F).
 
Expression of Per 61 in motor neurons of transgenic 
mice expressing mSOD1
 
G37R
 
Transgenic mice overexpressing by 6-fold (L29) or 12-fold
(L42) the G37R mutant of the 
 
SOD1
 
 gene linked to human
ALS develop a motor neuron-like disease (Wong et al., 1995).
The onset and severity of disease is increased in L42 compared
with L29, reflective of the increased SOD1
 
G37R
 
 transgene copy
number (Wong et al., 1995). Labeling of lumbar spinal cord
sections from L29 and L42 transgenic mice with anti–Per 56
showed a similar labeling to that obtained in Per transgenic
mice, with a specific and intense labeling of motor neurons
(Fig. 7, A and C). However, most interestingly, in contrast to
our findings in motor neurons of wild-type and peripherin
transgenic mice, Per 61 immunoreactivity was detected in mo-
tor neurons of both L29 and L42 SOD1
 
G37R
 
 transgenic mice
showing the presence of aggregates not only in perikarya but
also in proximal neurites. This labeling correlated with disease
onset, only rarely being observed in motor neurons of pres-
ymptomatic mice. Other smaller aggregates, similar to those
described previously using polyclonal peripherin antibody
(Julien and Beaulieu, 2000), were also labeled (Fig. 7, B and D,
arrowheads). Competition with the synthetic peptides used to
raise the antibodies showed the specificity of this labeling (Fig.
7, E and F). Moreover, RT-PCR of RNA extracted from spinal
Figure 4. Per 61 induces death of motor neurons 
in culture. (A) Plasmid expression vectors encoding 
the individual peripherin isoforms, Per 58, Per 56, 
Per 61, or vector alone (pRcCMV; control) were 
microinjected along with dextran-FITC into the 
nuclei of motor neurons in dissociated spinal cord 
cultures. Microinjected motor neurons, containing 
dextran-FITC, were identified by epifluorescence 
microscopy. The number of viable motor neurons 
were counted each day for 7 d and the results from 
each microinjection experiment compared. The 
chart shows the composite of three separate exper-
iments performed for each peripherin isoform. Per 
61 was extremely neurotoxic with  90% of the 
microinjected motor neurons dead within 7 d of 
expression. The effects of Per 56 and Per 58 on 
motor neuron viability were not significantly 
different from control. (B) Motor neurons micro-
injected with either Per 58, Per 56, or Per 61 were 
labeled by indirect immunofluorescence with anti-
body recognizing peripherin (MAB1527). It is note-
worthy that motor neurons in dissociated spinal 
cord cultures do not express detectable levels of 
peripherin and therefore expression of the peripherin 
isoforms in microinjected motor neurons could 
easily be detected using peripherin antibody. The 
results show the comparative cytoplasmic distribution 
of the peripherin isoforms after 3 d expression. Both 
Per 58 and Per 56 integrated normally into the 
existing cytoplasmic network with even distribution 
throughout the perikarya and neuritic processes. 
Apparent varicosities in peripherin labeling in the 
Per 58 expressing motor neuron are due to crossing 
of neurites from nonmicroinjected neurons that 
block the peripherin signal. In contrast, Per 61 
did not integrate into the existing IF network, but 
instead formed aggregates that were also present in 
neurites (arrows). Bar, 50  m. (C) Double immuno-
fluorescence labeling of microinjected motor neurons 
with monoclonal antibody to peripherin (MAB1527; 
red) and polyclonal antiserum to NF-L (AB1983; 
green) shows that both Per 58 and Per 56 colocalize 
with NF-L, whereas Per 61 disrupts the existing IF 
network (arrows). Bar, 30  m.T
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cord showed the presence of the mRNA for Per 61 in
SOD1
 
G37R
 
 transgenic mice (Fig. 7 G). These results show that,
in addition to Per 56, there is expression of Per 61 in motor
neurons of SOD1
 
G37R
 
 transgenic mice.
 
Selective anti–Per 61 labeling of motor neurons 
in ALS lumbar spinal cord
 
Although splice variants of peripherin have not been identi-
fied in human, the synthetic peptide used to generate the Per
61 antibody spans a region of intron 4 conserved at the nucle-
otide level between mouse, rat, and human (Foley et al.,
1994). Using the Per 61 antibody, we have labeled pathologi-
cal lesions in the lumbar spinal cord of two out of three famil-
ial ALS cases with no labeling detected in two control cases.
The Per 61 labeling was intense and correlated with the oc-
currence of peripherin abnormalities (as revealed with periph-
erin antibody). Fig. 8 shows the lumbar spinal cord sections
from a familial ALS case labeled with antibody to peripherin
(Fig. 8 A), with Per 61 antibody (Fig. 8, B and C), and se-
quential double labeling with Per 61 (3,4-diaminobenzidine
 
[
 
DAB]; brown) and antibody to peripherin (Fig. 8 D, alkaline
phosphatase, pink). Peripherin immunoreactivity localized
mainly to the motor neuron perikaryon and to spheroid struc-
tures (Fig. 8, black arrows) consistent with previous reports of
peripherin abnormalities in cases of ALS (Fig. 8 A; Corbo and
Hays, 1992; Migheli et al., 1993; Strong, 2001). Per 61 im-
munoreactivity was also predominantly localized to motor
neuron perikarya and less frequently to axonal spheroids (Fig.
8, B and C). Other similar structures were also present in both
peripherin-labeled and Per 61–labeled tissue (Fig. 8, A and B,
white arrows). Per 61 immunoreactivity appeared as speckles,
as has been observed in all the other experimental paradigms
tested (this is clearly apparent in the axonal spheroid shown in
the inset of Fig. 8 B, white arrow). In double labeling experi-
ments, Per 61 and peripherin immunoreactivity could be lo-
calized in many cases to the same motor neuron (Fig. 8 D).
 
Anti–Per 61 immunoprecipitates an abnormal 
peripherin species from ALS lumbar spinal cord tissue
 
Per 61 antibody was used in an immunoprecipitation assay
to verify that this antibody was indeed recognizing human
peripherin. Polyclonal peripherin antibody (AB1530) was
Figure 5. Characterization of specific antisera to peripherin
isoforms. (A–F) SW13 vim( ) cells transfected with plasmid expression 
vectors encoding Per 58, Per 56, or Per 61 were labeled by indirect 
immunofluorescence with anti–Per 56 or anti–Per 61. There was no 
labeling of Per 58 by either antibody (A and B). Both anti–Per 56 
and anti–Per 61 were specific for their respective proteins, Per 56 
appearing filamentous (D) and Per 61 speckled (E). Bars: (A–D and 
F) 20  m; (E) 30  m. (G) Immunblots of cell extracts from NIH 3T3 
cells transfected with Per 58 (lane 1), Per 56 (lane 2), or Per 61 (lane 
3) were probed with polyclonal antiserum to peripherin (Poly Per; 
AB1530); anti–Per 61 and anti–Per 56. The results obtained confirmed 
the specificity of the Per 56 and Per 61 antisera.
Figure 6. Expression of Per 56 in motor neurons of peripherin 
transgenic mice. (A–F) Lumbar spinal cord sections from wild-type 
(WT; A and B) and Per (C and D) and Per;LKO (E and F) transgenic 
mice were labeled immunocytochemically with anti–Per 56 and 
anti–Per 61. Per 56 expression was detected mildly in motor neurons 
of C57Bl6 mice (A, arrows) and strongly in both Per (C) and Per;
LKO (E) transgenic mice, forming aggregates in the latter (arrowheads). 
In contrast, no labeling of motor neurons was detected with anti–Per 
61 in spinal cord sections from C57Bl6 mice (B) or in either of the 
peripherin transgenic mice (D and F). Bar, 60  m.T
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also used to determine whether the increased peripherin im-
munoreactivity detected in two out of three familial ALS
cases tested correlated with an increased expression of pe-
ripherin. Lysates of lumbar spinal cord from the same ALS
cases used to generate the immunohistochemical data (Fig.
8) was used for the immunoprecipitation assays. Motor neu-
rons in these cases had peripherin abnormalities and were
labeled with Per 61 antibody. Control lumbar spinal cord
tissue, in which there was no Per 61 immunoreactivity
detected immunohistochemically, was also tested for com-
parison. Immunoblots of the resultant anti–Per 61 and anti-
peripherin immunoprecipitates were probed with monoclo-
nal peripherin antibody. In initial experiments, the RIPA-
insoluble fraction was exclusively used for immunoprecipita-
tion assays, as peripherin is normally localized to this frac-
tion. Although we detected an overall increase in peripherin
expression in ALS lumbar spinal cord tissue compared with
control tissue (Fig. 9), we did not detect a Per 61 species,
probing the blots with either monoclonal peripherin or
anti–Per 61. However, in experiments using transfected
SW13 vim(
 
 
 
) cells, we found that Per 61 partitioned largely
to the soluble fraction of cells lysed in RIPA buffer (unpub-
lished data), which is consistent with defects in the assembly
of Per 61 to form a detergent-insoluble IF network. Conse-
quently, the RIPA-soluble fraction was used for the anti–Per
61 immunoprecipitation assays. Results show that the Per
61 antibody immunoprecipitated a species that was detected
on immunoblots by the monoclonal peripherin antibody.
Moreover, this Per 61 species migrated at a slower rate than
the regular human peripherin (Fig. 9), which is consistent
with a predicted increase in molecular mass because of an
abnormal splicing event.
Figure 7. Expression of Per 61 in motor neurons of mutant SOD1
G37R 
transgenic mice. (A–F) Lumbar spinal cord sections from L29 (A and 
B) or L42 (C and D) mutant SOD1
G37R transgenic mice were labeled 
immunocytochemically with anti–Per 56 and anti–Per 61. Per 56 
expression was detected in motor neurons of both L29 and L42 
mutant SOD1
G37R transgenic mice (A and C, white arrows). Expres-
sion of Per 61 was also detected (B and D) with anti–Per 61 labeling 
aggregates in motor neuron perikarya and proximal axons (white 
arrows), in addition to smaller inclusions located in the surrounding 
neuronal tissue (arrowheads). E and F show ablation of the Per 56 or 
Per 61 immunoreactivity in the presence of the respective immuno-
genic peptides. Bar, 60  m. (G) RT-PCR of total RNA extracted from 
wild-type (WT) or mutant SOD1
G37R (L29; endstage) spinal cord 
using primers 56/58 to detect Per 56 (178 bp) and primers 61/58 to 
detect Per 61 (352 bp). Note the Per 61 PCR product apparent in 
the RNA sample derived from SOD1
G37R spinal cord (arrow).
Figure 8. Selective anti–Per 61 labeling of motor neurons in ALS 
lumbar spinal cord. Lumbar spinal cord sections from a familial ALS 
case labeled with antibody to peripherin (A); anti–Per 61 (B and C); 
and double labeled with anti–Per 61 (DAB, brown) and antibody to 
peripherin (D, alkaline phosphatase, pink). Peripherin antibody, as 
shown in A, labeled predominantly motor neuron perikaryon (large 
black arrow) and spheroidal structures (small black arrows). Neuritic 
processes were also labeled (white arrow). Per 61 specifically labeled 
motor neuron perikarya (B, large black arrows, and C, black arrows) 
and neuritic processes (B, white arrow). Spheroids were clearly 
apparent from the DAB labeling (B, small black arrows). The inset 
of B shows the speckled labeling in an axonal spheroid (indicated by 
white arrow) consistent with previous observations of Per 61 immuno-
reactivity, next to an unlabeled motor neuron perikaryon (inset, black 
arrow). The intensity of the Per 61 immunoreactivity in motor neuron 
perikarya is clearly apparent (C, black arrows). No labeling of control 
tissue was observed (not depicted). Per 61 immunoreactivity was 
colocalized with peripherin immunoreactivity in some (D, black 
arrow with asterisk), but not all motor neuron perikarya (D, black 
arrow). White arrow in D indicates small speroids. Bars: (A and B) 
30  m; (C) 70  m; and (D) 12  m.T
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Discussion
Here, we have demonstrated for the first time the in vivo
expression of alternatively spliced variants of peripherin
both normally and in a pathogenic setting. We have shown
expression of Per 61, an isoform demonstrated to be neuro-
toxic, in motor neurons of two lines of transgenic mice ex-
pressing mutant SOD1
G37R, but not in control mice or pe-
ripherin transgenic mice, demonstrating that the disease
mechanism of SOD1
G37R includes expression of a neuro-
toxic splice variant of peripherin. Furthermore, Per 61 im-
munoreactivity was detected in motor neurons of lumbar
spinal cord from two out of three familial ALS cases, the
Per 61 antibody immunoprecipitating a peripherin species
that had a higher molecular mass than regular peripherin
on SDS–polyacrylamide gels. These findings suggest that
aberrant splicing of the peripherin gene transcript can occur
in ALS.
Three peripherin isoforms, Per 58, Per 56, and Per 61,
were first identified at both the mRNA and protein levels in
a mouse neuroblastoma cell line (Landon et al., 1989,
2000). Per 58 is identical to the peripherin species described
by Portier and colleagues who first identified this type III IF
protein in mouse neuroblastoma and rat PC12 cells (Portier
et al., 1983a,b). Per 58 is encoded by all nine exons of the
peripherin gene and is the most predominant species de-
tected on immunoblots of neuronal tissue extracts. Per 61 is
generated by the retention of intron 4 of the peripherin gene
introducing a 32–amino acid insertion within coil 2 of the
conserved  -helical rod domain of Per 61. This insertion
contains three  -helix disrupting proline residues, thereby
potentially disrupting the filament forming capacity of Per
61. Per 56 is generated by the use of a cryptic acceptor site at
the beginning of exon 9, resulting in a peripherin species in
which the COOH-terminal 21 amino acids of Per 58 are re-
placed with a unique 8–amino acid sequence (Landon et al.,
1989). Per 56 has lost the COOH-terminal tyrosine of Per
58, which has been shown to be phosphorylated in several
systems (Angelastro et al., 1998). Although the purpose of
this COOH-terminal tyrosine phosphorylation of periph-
erin is unknown, its absence in Per 56 may have functional
consequences.
Cytoplasmic aggregates comprised of nIFs are a character-
istic feature of degenerating motor neurons in ALS and of
mouse models of ALS, including peripherin transgenic mice
and mice expressing mutant SOD1
G37R. How these aggre-
gates are formed is not known but may be related to the as-
sembly properties of the individual IF subunits or to the in-
teractions between different IF types, such as neurofilaments
and peripherin. This is especially relevant when it is consid-
ered that peripherin expression is increased after injury in
certain neuronal populations that normally only express
neurofilaments (Beaulieu et al., 2002). Moreover, the differ-
ential expression of peripherin splice variants, particularly
Per 61, may influence aggregate formation. In previous work
from this and other laboratories, peripherin generated from
ectopic expression of the peripherin gene in SW13 vim( )
cells showed that peripherin was capable of self-assembly to
form a filamentous network and could coassemble with the
neurofilament subunits to varying degrees, being capable of
coassembly with NF-L, but not with NF-M or NF-H (Cui
et al., 1995; Beaulieu et al., 1999b). The contribution of pe-
ripherin isoforms to filament assembly was not considered in
these previous studies. In this regard, we compared the as-
sembly properties of the peripherin isoforms, Per 58, Per 56,
and Per 61 either alone or coexpressed with the neurofila-
ment subunits in transfected SW13 vim( ) cells and in mi-
croinjected motor neurons in primary culture. Both Per 58
and Per 56 were competent for self-assembly to form fila-
mentous networks in SW13 vim( ) cells and were capable
of coassembly with the neurofilament subunits. Moreover,
Per 58 and Per 56 were assembly competent when expressed
in microinjected motor neurons in primary culture, appar-
ently interacting normally with the endogenous neurofila-
ment network. In contrast, Per 61 was assembly incompe-
tent, either when expressed alone or together with the
neurofilament subunits in SW13 vim( ) cells. In a further
study using SW13 cells stably expressing Per 58 and Per 56,
introduction of Per 61 by ectopic expression by transfection
of the Per 61 cDNA induced aggregation of both Per 58 and
Per 56 (unpublished results). Furthermore, Per 61 was as-
sembly incompetent in microinjected motor neurons, form-
ing aggregates in the perikaryon and neuritic processes,
disrupting the endogenous neurofilament network and in-
ducing cell death. Expression of Per 58 and Per 56 had no
significant effect on the viability of motor neurons com-
pared with control populations microinjected with vector
alone. These findings demonstrate that Per 61 expression is
toxic to motor neurons and that death correlates with the
formation of aggregates.
Using the isoform-specific antisera, expression of Per 56
and Per 61 was investigated in motor neurons of lumbar spi-
nal cord sections from two lines of peripherin transgenic
mice and from two lines of transgenic mice expressing mu-
Figure 9. Anti–Per 61 immunoprecipitation of higher molecular 
mass peripherin species. Anti–Per 61 and polyclonal peripherin 
(Poly Per) immunoprecipitates from ALS and control lumbar spinal 
cord tissue were resolved on a 10% SDS–polyacrylamide gel and 
transferred to PVDF membrane by electroblotting. The membrane 
was then immunoblotted with monoclonal peripherin antibody to 
detect peripherin species immunoprecipitated by Poly Per and anti–
Per 61. Increased peripherin expression was detected in the pellet 
fraction of ALS tissue immunoprecipitated with Poly Per (compare 
first two lanes). Anti–Per 61 immunoprecipitated a species from the 
supernatant fraction of ALS tissue that was recognized by the mono-
clonal peripherin antibody (lane 3, asterisk). This peripherin species 
had a retarded migration, indicative of an increased molecular mass 
(compare arrows indicating the migration position of regular peripherin 
[lower arrow] and Per 61 peripherin [higher arrow]). Contaminating 
IgG from the immunoprecipitation assay is indicated.T
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tant SOD1
G37R. Low levels of Per 56 expression was detected
in motor neurons of wild-type (C57Bl6) mice, whereas in-
creased labeling was detected in motor neurons of both pe-
ripherin and mutant SOD1
G37R transgenic mice. Expression
of Per 61 was not detected in motor neurons of wild-type or
peripherin transgenic mice but did occur in motor neurons
of SOD
G37R transgenic mice, demonstrating for the first
time differential expression of peripherin isoforms in a dis-
ease paradigm of ALS. The demonstrated neurotoxicity asso-
ciated with Per 61 expression in motor neurons in primary
culture suggests that abnormal Per 61 expression may con-
tribute to motor neuron degeneration in vivo.
The synthetic peptide used to generate the Per 61 anti-
body spans a region of intron 4 that is conserved at the nu-
cleotide level between mouse, rat, and human (Foley et al.,
1994). This suggested that the epitope recognized by anti–
Per 61 in mouse may exist as an equivalent peripherin iso-
form in human. Using this antibody, we labeled pathologi-
cal lesions in two out of three familial ALS cases with no
labeling detected in control cases. This immunoreactivity
correlated with the presence of peripherin abnormalities,
including labeling of motor neuron perikarya and axonal
spheroids, and could be colocalized to the same motor neu-
rons. This finding suggested that a similar abnormal splice
variant of peripherin was expressed in motor neurons in
ALS. However, from the only known gene sequence, intron
4 of human peripherin is 91 bp long, whereas in mouse it is
96 bp (Foley et al., 1994). This would mean that a com-
plete retention of intron 4 in human, as occurs in mouse to
generate Per 61, would lead to a frameshift, formation of a
premature stop codon, and generation of a truncated pe-
ripherin species. To test this possibility, we performed im-
munoprecipitation assays using the Per 61 antibody and
also commercially available peripherin polyclonal antise-
rum. Using this approach, we made three important find-
ings. First, the increased peripherin immunoreactivity ob-
served in the ALS cases tested was because of an increased
expression of peripherin. This is of interest when it is con-
sidered that peripherin expression can be induced in motor
neurons after neuronal injury (Troy et al., 1990), suggest-
ing that increased peripherin expression in ALS may be be-
cause of an injurious event. Second, the Per 61 antibody
immunoprecipitated a species from ALS pathological tissue
that was recognized by monoclonal peripherin antibody on
immunoblots. Third, this immunoprecipitated species ran
at a higher molecular mass than regular peripherin on
SDS–polyacrylamide gels, which is consistent with what
would be expected if a splicing abnormality were to occur.
Indeed, there is evidence from ESTs that it is possible to
have read through into intron 4 of the human peripherin
gene (GenBank/EMBL/DDBJ accession no. BE786797).
Although we have not as yet identified the specific splicing
event that would account for the Per 61 species, we have
detected it in ALS tissue. This does provide additional sup-
port that such abnormal splicing events can occur.
Expression of alternatively spliced variants has been de-
scribed for other IF proteins, including nuclear lamins
(Fisher et al., 1986; McKeon et al., 1986), glial fibrillary
acidic protein (Zelenika et al., 1995), and human synemin
(Titeux et al., 2001). Moreover, an alternative splice variant
of desmin is causative of some forms of cardiac and skeletal
myopathies (Park et al., 2000). Interestingly, most disease-
causing mutations of IF proteins are located within the
conserved  -helical rod domain, as has been most clearly
demonstrated for the keratins in numerous skin-blistering
diseases (Fuchs, 1994) and for desmin in several desmin-
related myopathies (Carlsson and Thornell, 2001). Per 61 has
many similarities to these previous findings, with a disrupted
 -helical rod domain having a dominant negative effect on
peripherin IF assembly and inducing motor neuron death.
Our findings demonstrate for the first time the in vivo ex-
pression of alternatively spliced variants of peripherin both
normally and in a pathogenic setting. The expression of Per
61 in motor neurons of transgenic mice expressing mutant
SOD1
G37R, but not of control mice or of peripherin trans-
genic mice, shows that the disease mechanism of SOD1
G37R
includes expression of a neurotoxic splice variant of periph-
erin. The detection of Per 61 specifically in motor neurons
and axonal spheroids in spinal cord of ALS cases suggests
that abnormal expression of alternatively spliced variants of
peripherin warrants further investigation.
Materials and methods
Transient transfections
A human adrenal carcinoma cell line, SW13 vim( ), that lacks cytoplas-
mic IFs, was derived by dilutional cloning of SW13 cells obtained from the
American Type Culture Collection. The calcium phosphate transfection
procedure was used as previously described (Beaulieu et al., 1999b). The
mouse peripherin isoform cDNAs, Per 56, Per 58, and Per 61 (provided by
Dr. Francoise Landon, CNRS UMR 7000, Paris, France [Landon et al.,
1989, 2000]), were subcloned into the BamH1-EcoRV site of pRcCMV (In-
vitrogen). Ectopic expression of each peripherin isoform in SW13 vim( )
cells was detected using peripherin monoclonal antibody (MAB1527;
CHEMICON International, Inc.) and isoform-specific rabbit polyclonal an-
tibodies that were raised to synthetic peptides corresponding to the unique
sequences within Per 61 (EWRCASQPGLSATAQ) and Per 56 (CLLRPQEL).
Each antiserum was purified by column affinity chromatography using the
respective antigenic peptide linked to Sepharose beads. The subcloning of
the neurofilament cDNAs has been described previously (Beaulieu et al.,
1999b). The yield of Per 61 from cell lysates of transfected SW13 vim( )
cells was low, reflecting the instability of this protein; therefore, an immu-
noprecipitation protocol similar to that described in Lindenbaum et al.
(1987) was used to obtain sufficient quantities of Per 61 for immunoblot-
ting. For later immunoblotting experiments, Per 61 was obtained directly
from cell lysates of transfected NIH3T3 cells, which have an endogenous
vimentin network that stabilizes Per 61, as was initially observed for NF-L.
Intranuclear microinjection of cultured motor neurons
Dissociated spinal cord cultures from E13 CD1 mice were prepared as de-
scribed previously (Durham et al., 1997; Roy et al., 1998). These cultures
contain numerous cell types including motor and DRG neurons, as-
trocytes, and microglia that can be identified morphologically and im-
munocytochemically using cell-specific markers (Durham et al., 1997;
Robertson et al., 2001). The pRcCMV expression vectors (100 ng/ l) incor-
porating Per 56, Per 58, or Per 61 were microinjected into motor neuronal
nuclei along with the fluorescent marker, 70-kD dextran-FITC (15 mg/ml;
Molecular Probes) according to the method of Durham et al. (1997). In-
jected motor neurons were identified by the presence of dextran-FITC
visualized by epifluorescence microscopy; morphology was evaluated
by phase microscopy. Viability was assessed daily by counting the num-
ber of motor neurons containing the marker. The number of viable neu-
rons counted on each day was normalized to the number present on day
1 after microinjection. Experiments were performed in triplicate cul-
tures, with 50–100 motor neurons on each coverslip surviving the injec-
tion.
Immunocytochemistry of cultured cells
SW13 vim( ) cells grown on glass coverslips were fixed in methanol for 5
min at  20 C and blocked for 30 min in 3% (wt/vol) BSA, 0.1% TritonT
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X-100 in PBS. For the motor neuron intranuclear microinjection studies,
the fixation method of Roy et al. (1998), was used. Immunocytochemistry
was performed using antibodies recognizing peripherin (monoclonal
MAB1527; polyclonal AB1530) and polyclonal antibodies to NF-L
(AB1983), NF-M (AB1981), and NF-H (AB1982); all were purchased from
CHEMICON International, Inc. and used at 1:1,000 diluted in blocking so-
lution. The generated rabbit polyclonal peripherin isoform-specific antise-
rum to Per 56 and Per 61 were both used at 1:500. Antibody distribution
was visualized by epifluorescence microscopy after incubation with sec-
ondary antibodies, anti–mouse/anti–rabbit IgG conjugated to Alexa Fluor
488 (green) or Alexa Fluor 594 (red) (diluted 1:250; Molecular Probes).
Immunoblotting
Cells were harvested in 62.5 mM Tris, pH 6.8, containing 2% SDS and
10% glycerol, and assayed for total protein using the bichinconinic acid
assay (Sigma-Aldrich). Loadings of 10–15  g of protein were routinely an-
alyzed on 7.5% (wt/vol) SDS–polyacrylamide gels and then blotted to the
polyvinyldiflouride (PVDF) membrane. For immunoblotting, membranes
were incubated with monoclonal antibodies recognizing peripherin (MAB1527,
1:5,000; anti–Per 56 and anti–Per 61, 1:500) or actin (1:10,000; Roche
Diagnostics) and antibody binding revealed with the ECL detection system
(NEN Life Science Products).
Transgenic mice
The mice used in this study have been characterized previously and in-
cluded C57Bl6 (wild-type, n   3); heterozygous transgenic mice overex-
pressing peripherin under control of the peripherin gene promoter in a
wild-type background (Per; n   2, age 7 mo; and n   1, age 23 mo) or NF-L
knockout background (Per;LKO; n    3, age 7 mo; Beaulieu et al.,
1999a); and two lines of transgenic mice expressing G37R mutant SOD1,
line 42 (L42; n   2, age 3 mo; n   2, age 4 mo; and n   2, age 5.5 mo),
which has an aggressive phenotype with death occurring at 6–7 mo of age;
and line 29 (L29; n   2, age 4 mo; n   2, age 6 mo; n   4, age 10.5–12
mo), which has a milder phenotype, reflective of the lower copy number
of integrated mutant SOD1 transgenes (Wong et al., 1995). All transgenic
mice were selected to include ages in which motor neuron degeneration is
apparent (Wong et al., 1995; Beaulieu et al., 1999a). For immunohis-
tochemical analysis of transgenic mouse tissue sections, the method of
Nguyen et al. (2001) was used. For RT-PCR, spinal cords were removed
from mice that had been killed by CO2 and total RNA extracted using TRI-
zol Reagent (Invitrogen). Total RNA was estimated at OD 260 and the re-
verse transcriptase reaction was performed using Superscript II RNase
H-Reverse transcriptase (Invitrogen). PCR was performed using 50 p.m. of
both sense and antisense primers, 2 U Taq DNA polymerase (Invitrogen)
and otherwise standard conditions for 35 cycles: 95 C for 30 s; 55 C for
1.5 min; and 72 C for 1 min. The sense and antisense primers flanked the
unique regions in Per 61 (61/58 primer pair) at nucleotide positions 2210–
2233 and 2857–2881, respectively, and Per 56 (56/58 primer pair) at
nucleotide positions 3637–3661 and 4567–4592, respectively. (Primer
sequences: 61/58, TCCCGCCTAGAACTGGAGCGCAAG and TGGCG-
GCGTCCGACAGGTCAGCAT; 56/58, TGCCTGAGATGGAGCCTCTC-
CAGGA and GCATGCAGAGCAGGACTGGATACAG). The expected sizes
of the PCR products using the 61/58 primer pair are 256 bp for Per 58 and
352 bp for Per 61. Correspondingly, the expected sizes of the PCR prod-
ucts using the 56/58 primer pair are 240 bp for Per 58 and 178 bp for Per
56 (Landon et al., 2000).
Human ALS cases
Three patients with familial ALS (46-yr-old female, 58-yr-old male, and 61-
yr-old male) were followed in the Motor Neuron Diseases Clinic at London
Health Sciences Center. The diagnosis of ALS was confirmed at autopsy. It
was unknown if these patients carried mutations in the SOD1 gene. The
two normal control cases (58-yr-old male and 75-yr-old female) were se-
lected on the basis of the absence of any neurologic deficits or neuro-
pathologic abnormalities at autopsy. Paraffin sections of lumbar spinal
cord from the ALS and control cases were rehydrated in a series of graded
ethanol washes and H2O and blocked for 1 h in 0.2% (wt/vol) Triton
X-100, 5% (wt/vol) BSA in PBS. Endogenous peroxidase activity was
blocked with 3% (vol/vol) hydrogen peroxide in PBS for 5 min followed by
three washes for 3 min in PBS. Peripherin antibody (AB1530; 1:1,000) and
Per 61 antibody (1:500) were diluted in 0.05% (wt/vol) Triton X-100, 5%
BSA in PBS. Antibody incubations were performed overnight at 4 C, and
the antigen–antibody complex was detected using the Vectastain Elite ABC
Kit (Vector Laboratories), with substrate developed using DAB and hydro-
gen peroxide. For double labeling with Per 61 and peripherin, the labeling
was done sequentially, first with Per 61 antibody (DAB), and then with pe-
ripherin antibody, using alkaline phosphatase as the substrate.
For immunoprecipitation with Per 61 antibody, 200 mg of lumbar spi-
nal cord from ALS or control cases was homogenized in 2 ml RIPA buffer
(20 mM Tris, pH 7.4, 137 mM NaCl, 1% NP-40, and 0.5% sodium deoxy-
cholate) containing 0.1% SDS and protease inhibitor cocktail (Sigma-
Aldrich). Homogenates were split into two 1-ml samples and centrifuged
at high speed in an Eppendorf microcentrifuge at 4 C for 10 min. Superna-
tants were removed and kept at 4 C. Pellets were solubilized in 1% SDS,
boiled for 5 min, and made to 0.1% SDS with RIPA buffer. The supernatant
and pellet fractions were preimmune absorbed for 45 min at 4 C with 50
 l protein A–Sepharose and 2  l Per 61 preimmune serum. Per 61 and pe-
ripherin polyclonal antiserum were cross-linked to 100  l of protein
A–Sepharose using disuccinimidyl suberate (Seize
TM X protein A Immuno-
precipitation Kit; Pierce Chemical Co.). The Sepharose-linked antibodies
were divided in two, and 50  l of each was added to the supernatant or
pellet fractions. Samples were rotated at 4 C for 2–3 h. The immunoprecip-
itates were pelleted using a microcentrifuge and washed five times with
RIPA buffer containing protease inhibitors. Protein recognized by the Per 61
antibody or peripherin antibody were released from the protein A–Sepha-
rose by boiling in Laemmli sample buffer. Immunoprecipitated protein, sep-
arated from the protein A–Sepharose by centrifugation, was loaded onto
10% SDS–polyacrylamide gels and blotted to PVDF membrane. For immu-
noblotting, membranes were incubated with peripherin monoclonal anti-
body (MAB1527; CHEMICON International, Inc.) and antibody binding re-
vealed using the ECL detection system (NEN Life Science Products).
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